| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
101.95(B) |
| Last
Volume: |
351,356 |
Avg
Vol: |
769,142 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
24,729 |
84,192 |
120,701 |
282,978 |
| Total Sell Value |
$23,631,267 |
$76,701,012 |
$107,160,703 |
$220,505,683 |
| Total People Sold |
7 |
13 |
15 |
17 |
| Total Sell Transactions |
14 |
38 |
55 |
116 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Landry Robert E |
EVP Finance CFO |
• – – |
2023-12-08 |
4 |
D |
$843.79 |
$854,759 |
D/D |
(1,013) |
30,686 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,199 |
23,599 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2023-12-08 |
4 |
D |
$843.79 |
$934,919 |
D/D |
(1,108) |
20,400 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
853 |
52,744 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2023-12-08 |
4 |
D |
$843.79 |
$682,626 |
D/D |
(809) |
51,891 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-12-05 |
4 |
AS |
$810.38 |
$5,342,787 |
D/D |
(6,536) |
59,421 |
|
9% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-12-04 |
4 |
D |
$813.58 |
$10,954,041 |
D/D |
(13,464) |
65,957 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-12-04 |
4 |
OE |
$270.43 |
$5,408,600 |
D/D |
20,000 |
79,421 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2023-12-01 |
4 |
AS |
$809.03 |
$81,730 |
D/D |
(100) |
18,447 |
|
11% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-11-14 |
4 |
AS |
$794.57 |
$5,188,213 |
D/D |
(6,492) |
59,421 |
|
21% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-11-13 |
4 |
D |
$795.69 |
$10,748,181 |
D/D |
(13,508) |
65,913 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2023-11-13 |
4 |
OE |
$270.43 |
$5,408,600 |
D/D |
20,000 |
79,421 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2023-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
400 |
52,700 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2023-11-07 |
4 |
AS |
$824.59 |
$82,790 |
D/D |
(100) |
18,547 |
|
16% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-11-01 |
4 |
AS |
$783.91 |
$783,910 |
D/D |
(1,000) |
19,803 |
|
22% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-11-01 |
4 |
OE |
$381.40 |
$381,400 |
D/D |
1,000 |
20,803 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2023-10-13 |
4 |
AS |
$850.00 |
$850,000 |
D/D |
(1,000) |
1,247 |
|
17% |
|
| Zoghbi Huda Y |
Director |
– • – |
2023-10-13 |
4 |
OE |
$391.92 |
$391,920 |
D/D |
1,000 |
2,247 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-10-02 |
4 |
AS |
$827.00 |
$858,426 |
D/D |
(1,038) |
19,803 |
|
17% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-10-02 |
4 |
OE |
$372.46 |
$386,613 |
D/D |
1,038 |
20,841 |
|
- |
|
| Guarini Kathryn |
Director |
– • – |
2023-09-08 |
4 |
A |
$0.00 |
$0 |
D/D |
240 |
240 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2023-09-08 |
4 |
A |
$0.00 |
$0 |
D/D |
240 |
240 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-09-01 |
4 |
AS |
$834.55 |
$208,638 |
D/D |
(250) |
19,803 |
|
10% |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2023-08-24 |
4 |
S |
$835.67 |
$5,216,073 |
D/D |
(6,197) |
21,508 |
|
-10% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-08-23 |
4 |
S |
$844.00 |
$188,212 |
D/D |
(223) |
31,699 |
|
-8% |
|
2406 Records found
|
|
Page 6 of 97 |
|
|
5.80 (0.6%) 
